Literature DB >> 11102984

BTK mutations in patients with X-linked agammaglobulinemia: lack of correlation between presence of peripheral B lymphocytes and specific mutations.

L Tao1, M Boyd, G Gonye, B Malone, J Schwaber.   

Abstract

X-linked agammaglobulinemia (XLA) is a human antibody deficiency that results from mutation of the tyrosine kinase btk. We tested the hypothesis that XLA patients who varied from the classic phenotype of XLA by presence of normal or near normal number of peripheral B lymphocytes would have a set of mutations of BTK that is different from the mutations found in patients without peripheral B lymphocytes. The mutations of BTK we found in two patients with normal numbers of peripheral B lymphocytes have been previously identified in patients without peripheral B lymphocytes. A third patient, without peripheral B cells, was found to express normal levels of wild type btk. Exmination of the mutations of the BTK gene in patients in the BTKbase who were identified as having peripheral B lymphocytes found that these same mutations, or mutations of the same protein domains, were also present in patients identified as lacking peripheral B lymphocytes. Analysis of mutations in BTK has previously led to the conclusion that severity of disease in XLA cannot be predicted from the specific mutation of BTK. The results of this study suggest that whether an XLA patient will develop peripheral B lymphocytes cannot be predicted from the specific mutation of BTK. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11102984     DOI: 10.1002/1098-1004(200012)16:6<528::AID-HUMU12>3.0.CO;2-T

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  2 in total

1.  Evaluating Acalabrutinib In The Treatment Of Mantle Cell Lymphoma: Design, Development, And Place In Therapy.

Authors:  Jennifer Girard; John Reneau; Sumana Devata; Ryan A Wilcox; Mark S Kaminski; Jessica Mercer; Shannon Carty; Tycel J Phillips
Journal:  Onco Targets Ther       Date:  2019-09-30       Impact factor: 4.147

Review 2.  Agammaglobulinemia: from X-linked to Autosomal Forms of Disease.

Authors:  Melissa Cardenas-Morales; Vivian P Hernandez-Trujillo
Journal:  Clin Rev Allergy Immunol       Date:  2021-07-09       Impact factor: 10.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.